PD1-Based TWIST1 Cancer Vaccine
- Therapeutic Biologics
- Reference No.
Key Problem and Market Opportunity
Key Advantages of the Technology
- Eliciting long-term memory CD8+ T responses against tumors.
- Demonstrated efficacy in treating mesothelioma and breast cancer
Potential Product and Services
Cancer vaccines that enhance immunotherapy against tumors
- US Provisional Application No. 62/978,911
- Patent application submitted